Aller au contenu principal
Fermer

Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers
information fournie par Boursorama CP 10/03/2021 à 17:45
Ajouter Boursorama à vos sources

Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers

- Enrollment of the first patient is expected in Q2 2021
- Trial will focus on patients without liver metastases, based on encouraging data in Phase Ib/II study
- Trial targets indications where clinical outcomes can be improved versus standard therapeutic options and immune checkpoint inhibitors ("ICIs")
- Continued clinical collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to conduct the expanded Phase II study

.../...

Valeurs associées

0,8020 EUR Euronext Paris -0,62%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.

89,37 -0,02%
Or
4 458,8 0,00%
8 401,18 +0,98%
1,15822 0,00%
0,543 +15,04%
Chargement...